Livzon Pharmaceutical Group Inc. (HKG: 1513)

Market Cap	31.99B
Revenue (ttm)	13.13B
Net Income (ttm)	2.24B
Shares Out	n/a
EPS (ttm)	2.42
PE Ratio	14.26
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jul 8, 2024

Volume	701,314
Open	26.85
Previous Close	27.10
Day's Range	26.85 - 27.60
52-Week Range	22.85 - 34.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,933
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2023, Livzon Pharmaceutical Group's revenue was 12.43 billion, a decrease of -1.58% compared to the previous year's 12.63 billion. Earnings were 1.95 billion, an increase of 2.32%.

Financial numbers in CNY